ArticleFrontiers in oncology2026
Gynecologic radiation oncology practice: retrospective analysis of a tertiary radiotherapy referral center.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to characterize gynecologic cancers in radiation oncology practice and compare survival outcomes with those reported in countries exhibiting a high or very high human development index. Methods: A retrospective review was conducted involving the medical records of all patients (n = 11,720) treated at our radiotherapy center between January 2012 and December 2022. Of these, 911 women with gynecologic cancers who underwent treatment and follow-up at our center were included in the analysis. Demographic, disease-related, and treatment-related characteristics, as well as relapse patterns and survival outcomes, were recorded and analyzed. Results: Gynecologic cancers (30%) ranked second among malignancies of women in radiation oncology, after breast cancer (35%). The two most common gynecologic cancers among all female malignancies in radiation oncology were corpus uteri cancer (20%, rank second after breast cancer) and cervical cancer (9%, rank third). With the exception of ovarian cancer, most gynecologic cancers were referred for radiotherapy at FIGO stages I-II (75%, n = 680). Curative and adjuvant radiotherapy rates were 95% (n = 771) and 75% (n = 580), respectively. The most frequently administered radiotherapy technique was external beam radiotherapy combined with brachytherapy (53%, n = 419). The rate of brachytherapy application in gynecologic radiation oncology was 82%. Palliative radiotherapy was most commonly administered for ovarian cancer (57%) in gynecologic oncology. The primary indication for palliative RT was pain management (42%). Relapse predominantly occurred as distant metastases in corpus uteri and cervical cancers, whereas other gynecologic cancers commonly exhibited locoregional disease. Survival outcomes, except for vaginal cancer, were comparable to those reported in the literature. Conclusions: Gynecologic cancers constitute a substantial proportion of radiation oncology practice in women. Survival outcomes at our center largely align with those observed in countries exhibiting a high or very high human development index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.